Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms

Cancer Treatment Reviews

Volumn 40, Issue 7, 2014, Pages 883-891

  Liu, Sariah ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Polymorphism; Targeted therapy; Toxicity

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ANTINEOPLASTIC AGENT; AZD 8330; BEVACIZUMAB; BREAST CANCER RESISTANCE PROTEIN; BUDESONIDE; CETUXIMAB; CRIZOTINIB; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ERLOTINIB; HLA DQA1 ANTIGEN; IMATINIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NILOTINIB; PANITUMUMAB; SELUMETINIB; SUNITINIB; TRAMETINIB; VANDETANIB; VASCULOTROPIN;

ARTERY THROMBOSIS; BLEEDING; DEPIGMENTATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG MONITORING; DRUG SAFETY; DYSLIPIDEMIA; EYE TOXICITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTHYROIDISM; IMMUNE RESPONSE; LIVER TOXICITY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEINURIA; QT PROLONGATION; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; WELLBEING;

POLYMORPHISM; TARGETED THERAPY; TOXICITY;

ANIMALS; ANTIBODIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MOLECULAR TARGETED THERAPY; POLYMORPHISM, GENETIC; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84901979851     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.05.003     Document Type: Review

References (107)

1. Liebler D.C., Guengerich F.P. Elucidating mechanisms of drug-induced toxicity. Nat Rev Drug Discov 2005, 4:410-420.
2. Campillos M., Kuhn M., Gavin A.C., et al. Drug target identification using side-effect similarity. Science 2008, 321:263-266.
3. Hunter T. Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell Biol 2009, 21:140-146.
4. Bradshaw R.A., Chalkley R.J., Biarc J., et al. Receptor tyrosine kinase signaling mechanisms: devolving TrkA responses with phosphoproteomics. Adv Biol Regul 2013, 53:87-96.
5. Shah D.R., Shah R.R., Morganroth J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf 2013, 36:413-426.
6. Li T., Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009, 4:107-119.
7. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?. Oncology (Williston Park) 2003, 17:23-28.
8. Liu H.B., Wu Y., Lv T.F., et al. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS ONE 2013, 8:e55128.
9. Petrelli F., Borgonovo K., Cabiddu M., et al. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer 2012, 78:8-15.
10. Lu J.F., Eppler S.M., Wolf J., et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 2006, 80:136-145.
11. Rudin C.M., Liu W., Desai A., et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 2008, 26:1119-1127.
12. Liu G., Gurubhagavatula S., Zhou W., et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenom J 2008, 8:129-138.
13. Su X., Lacouture M.E., Jia Y., et al. Risk of high-grade skin rash in cancer patients treated with cetuximab-an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology 2009, 77:124-133.
14. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010, 11:21-28.
15. Orditura M., De Vita F., Galizia G., et al. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. Oncol Rep 2009, 21:1023-1028.
16. Petrelli F, Borgonovo K, Barni S. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol; 2013.
17. Graziano F., Ruzzo A., Loupakis F., et al. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol 2008, 26:1427-1434.
18. Adjei A.A., Cohen R.B., Franklin W., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008, 26:2139-2146.
19. Cohen R.B., Aamdal S., Nyakas M., et al. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur J Cancer 2013, 49:1521-1529.
20. Falchook G.S., Lewis K.D., Infante J.R., et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13:782-789.
21. Balagula Y., Barth Huston K., Busam K.J., et al. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs 2010, 29:1114-1121.
22. Infante J.R., Fecher L.A., Falchook G.S., et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13:773-781.
23. Shapiro G.I., Rodon J., Bedell C., et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2014, 20:233-245.
24. Yap T.A., Yan L., Patnaik A., et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 2011, 29:4688-4695.
25. Ramirez-Fort MK, Case EC, Rosen AC, et al. Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis. Am J Clin Oncol; 2012.
26. Gomez-Fernandez C., Garden B.C., Wu S., et al. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. Eur J Cancer 2012, 48:340-346.
27. Cusatis G., Gregorc V., Li J., et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 2006, 98:1739-1742.
28. Lemos C., Giovannetti E., Zucali P.A., et al. Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics 2011, 12:159-170.
29. Kirkali Z. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use. BJU Int 2011, 107:1722-1732.
30. Hong D.S., Bowles D.W., Falchook G.S., et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2012, 18:4173-4182.
31. Papadopoulos KP, Tabernero J, Markman B, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. Clin Cancer Res; 2014.
32. Vermorken J.B., Trigo J., Hitt R., et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007, 25:2171-2177.
33. Genentech: Avastin prescription information; 2013. <>. http://www.gene.com/download/pdf/avastin_prescribing.pdf.
34. Rini B.I., Cohen D.P., Lu D.R., et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011, 103:763-773.
35. George S., Reichardt P., Lechner T., et al. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol 2012, 23:3180-3187.
36. Eechoute K., van der Veldt A.A., Oosting S., et al. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther 2012, 92:503-510.
37. Kim J.J., Vaziri S.A., Rini B.I., et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 2012, 118:1946-1954.
38. Osterlund P., Soveri L.M., Isoniemi H., et al. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 2011, 104:599-604.
39. Tahover E., Uziely B., Salah A., et al. Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Med Oncol 2013, 30:327.
40. Lombardi G., Zustovich F., Farina P., et al. Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature. Anticancer Drugs 2013, 24:90-97.
41. Schneider B.P., Wang M., Radovich M., et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008, 26:4672-4678.
42. Morita S., Uehara K., Nakayama G., et al. Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 2013, 71:405-411.
43. Etienne-Grimaldi M.C., Formento P., Degeorges A., et al. Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. Br J Clin Pharmacol 2011, 71:921-928.
44. Scartozzi M., Galizia E., Chiorrini S., et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009, 20:227-230.
45. Schmidinger M., Vogl U.M., Bojic M., et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?. Cancer 2011, 117:534-544.
46. Clemons J., Gao D., Naam M., et al. Thyroid dysfunction in patients treated with sunitinib or sorafenib. Clin Genitourin Cancer 2012, 10:225-231.
47. Izzedine H., Massard C., Spano J.P., et al. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 2010, 46:439-448.
48. GlaxoSmithKline: Pazopanib prescribing information; 2013. <>. https://www.gsksource.com/gskprm/htdocs/documents/VOTRIENT-PI-MG.PDF.
49. FDA: COMETRIQ prescribing information; 2012. <>. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf.
50. Rosenbaum S.E., Wu S., Newman M.A., et al. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 2008, 16:557-566.
51. Brazzelli V., Grasso V., Barbaccia V., et al. Hair depigmentation and vitiligo-like lesions in a leukaemic paediatric patient during chemotherapy with dasatinib. Acta Derm Venereol 2012, 92:218-219.
52. Hussain S.Z., Asghar A., Ikram M., et al. Development of skin hypopigmentation in a patient with metastatic papillary carcinoma thyroid treated with Sorafenib. BMC Endocr Disord 2013, 13:29.
53. Arora B., Kumar L., Sharma A., et al. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol 2004, 15:358-359.
54. Hapani S., Sher A., Chu D., et al. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 2010, 79:27-38.
55. Je Y., Schutz F.A., Choueiri T.K. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009, 10:967-974.
56. Ranpura V., Hapani S., Chuang J., et al. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010, 49:287-297.
57. Choueiri T.K., Schutz F.A., Je Y., et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010, 28:2280-2285.
58. Iclusig.com: Posatinib toxicity; 2013. <>. http://www.iclusig.com/.
59. Nalluri S.R., Chu D., Keresztes R., et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008, 300:2277-2285.
60. Hapani S., Chu D., Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009, 10:559-568.
61. Qi WX, Sun YJ, Tang LN, et al. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Crit Rev Oncol Hematol; 2013.
62. Naing A., Veasey-Rodrigues H., Hong D.S., et al. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol 2012, 23:2960-2963.
63. AstraZeneca: Vandetanib package insert; 2011. <>. http://www1.astrazeneca-us.com/pi/vandetanib.pdf.
64. European-Medicines-Agency: Nilotinib product characteristics; 2013. <>. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000798/WC500034394.pdf.
65. Norvartis: Nilotinib package insert; 2010. <>. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022068s004s005lbl.pdf.
66. Pfizer: Crizotinib package insert; 2011. <>. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202570s002lbl.pdf.
67. GlaxoSmithKline: Lapatinib package insert; 2013. <>. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf.
68. Deeken J.F., Shimkus B., Liem A., et al. Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors. Cancer Chemother Pharmacol 2013, 71:1473-1483.
69. AstraZeneca: Iressa prescribing information; 2010. <>. http://www.iressa.com/_mshost5259502/content/6906430/Gefitinib-product-informationasdad.
70. Spraggs C.F., Budde L.R., Briley L.P., et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011, 29:667-673.
71. Kijima T., Shimizu T., Nonen S., et al. Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism. J Clin Oncol 2011, 29:e588-e590.
72. Brown-Glberman U. Hepatic injury associated with bevacizumab use in metastatic breast and colon cancers: a review of two cases. Commun Oncol 2008, 5:539-542.
73. Huillard O., Bakalian S., Levy C., et al. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review. Eur J Cancer 2014, 50:638-648.
74. Renouf D.J., Velazquez-Martin J.P., Simpson R., et al. Ocular toxicity of targeted therapies. J Clin Oncol 2012, 30:3277-3286.
75. van der Noll R., Leijen S., Neuteboom G.H., et al. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treat Rev 2013, 39:664-672.
76. Esmaeli B., Prieto V.G., Butler C.E., et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer 2002, 95:881-887.
77. Sosman J.A., Kim K.B., Schuchter L., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714.
78. Busaidy N.L., Farooki A., Dowlati A., et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 2012, 30:2919-2928.
79. Crouthamel M.C., Kahana J.A., Korenchuk S., et al. Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res 2009, 15:217-225.
80. Hoogeveen R.C., Ballantyne C.M., Pownall H.J., et al. Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. Transplantation 2001, 72:1244-1250.
81. Naing A., LoRusso P., Fu S., et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res 2012, 18:2625-2631.
82. Perez-Soler R., Zou Y., Li T., et al. The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab. Clin Cancer Res 2011, 17:6766-6777.
83. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658-1664.
84. Fracasso P.M., Burris H., Arquette M.A., et al. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 2007, 13:986-993.
85. Khan K.H., Yap T.A., Yan L., et al. Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J Cancer 2013, 32:253-265.
86. Karthaus M., Ballo H., Abenhardt W., et al. Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer. Oncology 2005, 68:326-332.
87. Elkind N.B., Szentpetery Z., Apati A., et al. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 2005, 65:1770-1777.
88. Steeghs N., Gelderblom H., Roodt J.O., et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 2008, 14:3470-3476.
89. Dechend R., Luft F.C. Angiogenesis factors and preeclampsia. Nat Med 2008, 14:1187-1188.
90. Ranpura V., Pulipati B., Chu D., et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010, 23:460-468.
91. Janku F., Huang H.J., Angelo L.S., et al. A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R): implications for inhibition of the IGF-1R signal. Oncotarget 2013, 4:463-473.
92. Weihua Z., Tsan R., Huang W.C., et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008, 13:385-393.
93. Eremina V., Jefferson J.A., Kowalewska J., et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008, 358:1129-1136.
94. Halaban R., Moellmann G. White mutants in mice shedding light on humans. J Invest Dermatol 1993, 100:176S-185S.
95. Spritz R.A., Holmes S.A., Ramesar R., et al. Mutations of the KIT (mast/stem cell growth factor receptor) proto-oncogene account for a continuous range of phenotypes in human piebaldism. Am J Hum Genet 1992, 51:1058-1065.
96. Lazar-Molnar E., Hegyesi H., Toth S., et al. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000, 12:547-554.
97. Iwamoto T., Takahashi M., Ohbayashi M., et al. The ret oncogene can induce melanogenesis and melanocyte development in Wv/Wv mice. Exp Cell Res 1992, 200:410-415.
98. Moss K.G., Toner G.C., Cherrington J.M., et al. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther 2003, 307:476-480.
99. Kilickap S., Abali H., Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003, 21:3542. author reply 3543.
100. Elice F., Jacoub J., Rickles F.R., et al. Hemostatic complications of angiogenesis inhibitors in cancer patients. Am J Hematol 2008, 83:862-870.
101. Kamba T., McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007, 96:1788-1795.
102. Heinzerling J.H., Huerta S. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg 2006, 63:334-337.
103. Lu Z., Wu C.Y., Jiang Y.P., et al. Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Sci Transl Med 2012, 4:131ra50.
104. Andrade R.J., Lucena M.I., Alonso A., et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 2004, 39:1603-1612.
105. Teng J.F., Mabasa V.H., Ensom M.H. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors. Ther Drug Monit 2012, 34:85-97.
106. Joerger M., Kraff S., Huitema A.D., et al. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. Clin Pharmacokinet 2012, 51:607-617.
107. Gamelin E., Delva R., Jacob J., et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:2099-2105.